Figure 1.

Both CYP17A1 expression and DHEA secretion are increased in malignant GBM. (a) The medium from SVG-P12 and U87MG cells were collected and subjected to DHEA ELISA. Data are expressed as the means±s.e.m. (**P<0.01). The cell lysates were subjected to western blotting. (b) CYP17A1 mRNA expression was analyzed by the oncomine website and the correlation with patient survival was analyzed by the SurvExpress website. (c) Upper panel: western blotting for CYP17A1. Lower panel: the cultured medium was collected and subjected to ELISA. The experiments were performed independently three times, and the data are expressed as the means±s.e.m. (*P<0.05, **P<0.01). (d) Western blot of CYP17A1 expression. (e, f) U373MG cell lines were subjected to invasion and colony formation assays. (g) Effect of TMZ on cell survival characterized by colony formation assay. (h) After CYP17A1 knockdown, a colony formation assay (left panel) with U87MG-R cells was performed and quantified (middle panel). Data are expressed as the means ± s.e.m. (***P<0.001), #P<0.05 is the comparison between samble and shCYP17A1 at the same dose of TMZ. Subsequently, the cells were collected and subjected to western blotting with anti-CYP17A1 or anti-caspase antibodies (right panel). (i) Left, effect of abiraterone on CYP17A1 expression; right, after treatment for 24 h, media from U87MG was collected for ELISA. (j) After pretreatment with 20 μm abiraterone for 24 h, cells were treated with TMZ for the additional 24 h. Lysates were collected for western blotting. ELISA, enzyme-linked immunosorbent assay.